In recent years, psychedelic-assisted therapy has emerged as a promising frontier in the treatment of various psychiatric disorders, ranging from depression and anxiety to PTSD and addiction. Despite the mounting clinical evidence supporting its efficacy, therapeutic outcomes have demonstrated significant variability across patients, with some individuals experiencing profound, lasting benefits, while others show minimal or transient improvements. This variability has driven an intensive debate within the scientific community aimed at delineating the factors that predict successful responses to these treatments. Until now, research has largely concentrated on the phenomenology of the acute psychedelic experience itself, such as the intensity and nature of the subjective effects during dosing sessions. However, a groundbreaking new study published in Nature Mental Health has shifted the focus toward a more nuanced understanding of baseline patient characteristics and preparatory elements, as well as incorporating the hard-earned insights of therapists actively engaged in psychedelic-assisted therapy.
The study, spearheaded by Viljoen, Bendau, Walter, and colleagues, represents one of the first large-scale cross-sectional surveys to systematically canvass the perspectives of therapists who operate on the front lines of psychedelic treatment. This research gathered responses from 158 therapists experienced with varying substances, including psilocybin and ketamine, across different regulatory and practice settings. By employing both quantitative rating scales and qualitative thematic analysis of open-ended responses, the study provides a comprehensive examination of the predictors therapists believe are most influential in shaping long-term therapeutic outcomes.
One of the most remarkable findings reported by the therapists was the paramount importance of the therapeutic alliance formed between clinician and patient prior to and throughout the psychedelic experience. This alliance—understood as a relationship characterized by trust, empathy, and collaborative engagement—was consistently rated as the single most potent predictor of favorable outcomes. The data underscore how the establishment of a secure and supportive interpersonal context enhances patients’ willingness to confront challenging emotions and psychological material during sessions, thus deepening potential healing effects.
Equally vital according to therapists are patients’ baseline social support networks. Robust social integration outside of therapy was identified as a critical element that bolsters therapeutic gains and helps cement positive changes post-intervention. This finding dovetails with prior psychological models that emphasize the buffering effects of social relationships on mental health and highlights the necessity of considering patients’ broader psychosocial ecosystems during screening and preparation.
Personality traits emerged as another influential domain in the therapeutic response to psychedelics. Particularly, traits such as openness to experience and a capacity to surrender or relinquish control during the psychedelic session were attributed high importance by therapists. This aligns with increasing evidence from psychometric studies that suggest such traits may not only predict acute experiential qualities but also modulate the neurological and psychological mechanisms through which psychedelics exert their therapeutic action.
Notably, attachment style—a measure of how individuals form and maintain interpersonal relationships—was also rated as a significant factor. Secure attachment patterns correlated with better therapeutic outcomes, perhaps due to enhanced resilience and emotional regulation, which enable individuals to navigate the complex emotions that arise during psychedelic sessions. Conversely, insecure attachment may introduce additional therapeutic challenges that require tailored interventions.
Intriguingly, therapists’ beliefs about the mode of therapeutic action played a substantial role in shaping their perceptions of efficacy. Those who endorsed an active model of therapy—where the substance-induced experience functions as an opportunity for psychological insight and transformation actively facilitated by therapist guidance—consistently rated outcomes more favorably than those subscribing to more passive, drug-centered explanations.
Conversely, one of the predictors most widely perceived as undermining therapeutic response was patients’ prior use of nonpsychedelic substances. Therapists noted that such history could complicate treatment by introducing physiological tolerance, psychological resistance, or confounding expectation effects, thereby diminishing psychedelic efficacy. This insight may have profound implications for pre-treatment screening and patient selection criteria.
The study also illuminated how contextual variables related to therapists’ practice settings and their primary substance of experience influenced their evaluations. Those operating in unregulated or non-clinical environments appeared more accepting of certain challenging features of psychedelic experiences, possibly reflecting a greater familiarity with the unpredictable dynamics of these settings. Meanwhile, therapists utilizing psilocybin placed comparatively greater emphasis on preparation phases and sustained therapeutic presence throughout the session than those relying predominantly on ketamine—a substance with a distinct pharmacology and shorter session profile.
Qualitative analyses further enriched these findings by emphasizing the multifaceted nature of preparation and integration in modulating outcomes. Therapists highlighted that adequate preparation involves fostering a mindset grounded in openness, trust, and realistic expectations, paired with efforts to optimize the environmental context to promote safety and comfort. Similarly, thoughtful integration work—helping patients assimilate insights and behavioral changes into everyday life—was deemed indispensable in sustaining therapeutic gains.
These insights collectively challenge the prevailing paradigm that primarily valorizes the psychedelic’s acute pharmacological effects. Instead, they advocate for a more holistic approach that integrates patient baseline constitution, therapist-patient relational dynamics, and comprehensive preparatory and post-session support. This may necessitate revising clinical protocols and training programs to equip therapists with refined skills in alliance-building, patient assessment, and individualized preparation strategies.
The implications of this study are vast, as they pave the way for evidence-informed enhancements in screening, preparation, and integration frameworks for psychedelic-assisted therapy. These refinements could optimize patient selection, increase therapeutic efficacy, and minimize adverse responses. Furthermore, the differential weighting of predictors depending on the therapeutic substance used suggests the need for bespoke protocols aligned with the unique pharmacodynamics and session characteristics of psilocybin versus ketamine.
In conclusion, this landmark research by Viljoen and colleagues marks an important step in unraveling the complex interplay of psychological, interpersonal, and contextual factors that shape outcomes in psychedelic-assisted therapy. By centering the views of therapists actively engaged in delivering these treatments, it underscores the indispensable role of human factors beyond the pharmacological substrate. As the field advances into broader clinical deployment, integrating these lessons could prove pivotal in making psychedelic therapy a reliably transformative tool for mental health care worldwide.
Subject of Research:
Psychedelic-assisted therapy outcome predictors based on therapist perspectives.
Article Title:
Therapist-rated predictors of response to psychedelic-assisted therapy.
Article References:
Viljoen, G., Bendau, A., Walter, H. et al. Therapist-rated predictors of response to psychedelic-assisted therapy. Nat. Mental Health (2026). https://doi.org/10.1038/s44220-026-00642-4
DOI:
https://doi.org/10.1038/s44220-026-00642-4
